{
    "organizations": [],
    "uuid": "25a621d3bbcdcfae65ad19cd16f7a942e6f84dd4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hikma-pharmaceuticals-says-us-subs/brief-hikma-pharmaceuticals-says-us-subsidiary-launches-dexrazoxane-for-injection-idUSFWN1RM0CA",
    "ord_in_thread": 0,
    "title": "BRIEF-Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For Injection",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20 (Reuters) - Hikma Pharmaceuticals PLC:\n* HIKMA LAUNCHES DEXRAZOXANE FOR INJECTION * US SUBSIDIARY WEST-WARD PHARMACEUTICALS, LAUNCHED DEXRAZOXANE FOR INJECTION, 250MG AND 500MG VIALS, GENERIC EQUIVALENT TO ZINECARD Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-20T16:08:00.000+03:00",
    "crawled": "2018-04-21T18:03:50.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "hikma",
        "pharmaceutical",
        "plc",
        "hikma",
        "launch",
        "dexrazoxane",
        "injection",
        "u",
        "subsidiary",
        "pharmaceutical",
        "launched",
        "dexrazoxane",
        "injection",
        "250mg",
        "500mg",
        "vial",
        "generic",
        "equivalent",
        "zinecard",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}